Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing stu...
Sparad:
| Huvudupphov: | , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Elsevier
2024-06-01
|
| Serie: | Translational Oncology |
| Ämnen: | |
| Länkar: | http://www.sciencedirect.com/science/article/pii/S193652332400072X |
| Taggar: |
Inga taggar, Lägg till första taggen!
|